Indeed, systemic administration of IFNγ increased levels of CXCL10 and intratumoral T cell infiltration in a phase 0 clinical trial for sarcoma, and intratumoral injection of IFNγ increased tumor CXCL10 and CXCL11 in melanoma patients [37, 38]. Here, CXCL11 is linked to melanoma.